- Home
- SOCA vs MDWD Comparison
SOCA vs MDWD Comparison
Compare SOCA & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SOCA | MDWD |
|---|---|---|
| Founded | 2025 | 2000 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 235.0M | 230.7M |
| IPO Year | 2025 | 2014 |
Fundamental Metrics
Financial Performance| Metric | SOCA | MDWD |
|---|---|---|
| Price | $10.09 | $17.74 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $37.50 |
| AVG Volume (30 Days) | 28.5K | ★ 79.1K |
| Earning Date | 01-01-0001 | 11-20-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $20,932,000.00 |
| Revenue This Year | N/A | $15.89 |
| Revenue Next Year | N/A | $25.33 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 6.15 |
| 52 Week Low | $9.94 | $14.14 |
| 52 Week High | $10.15 | $22.51 |
Technical Indicators
Market Signals| Indicator | SOCA | MDWD |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 48.46 |
| Support Level | N/A | $17.23 |
| Resistance Level | N/A | $18.18 |
| Average True Range (ATR) | 0.00 | 0.74 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 49.78 |
Price Performance
Historical ComparisonAbout SOCA Solarius Capital Acquisition Corp. Class A Ordinary Share
Solarius Capital Acquisition Corp is a blank check company.
About MDWD MediWound Ltd.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.